Immune　checkpoint　inhibitor　(ICI)　therapy　is　the　new　standard　treatment　for　advanced　or　metastatic　hepatocellular　carcinoma　(HCC);　however,　many　patients　still　fail　to　respond.　This　study　explored　the　expression　and　prognosis　of　programmed　death　ligand　1　(PD-L1),　cluster　of　differentiation　24　(CD24),　and　cluster　of　differentiation　47　(CD47)　in　patients　with　hepatitis　B　virus-associated　HCC　(HBV-associated　HCC).　We　analyzed　sequencing　data　from　the　Cancer　Genome　Atlas　(TCGA)　and　investigated　the　expression　of　PD-L1,　CD24,　and　CD47　in　HBV-associated　HCC　patients　by　immunohistochemistry　and　their　relationship　with　prognosis　and　clinicopathological　factors.　HCC　data　from　the　TCGA　database　show　that　PD-L1　was　substantially　correlated　with　various　immune　cells.　In　67　patients　with　HBV-associated　HCC,　high　PD-L1　and　CD24　expression　levels　were　related　to　poor　overall　survival　(OS)　and　progression-free　survival　(PFS).　PD-L1　expression　was　significantly　associated　with　the　staging　of　HBV-associated　HCC　(p　=　0.011)　and　Ki67　expression　(p　=　0.024).　Correlation　analysis　between　variables　reveals　that　PD-L1　was　significantly　positively　correlated　with　CD24　and　CD47.　High　expression　of　PD-L1　and　CD24　are　risk　factors　for　poor　prognosis　in　HBV-associated　HCC　patients　following　curative　resection.　PD-L1　is　significantly　correlated　with　CD24　and　CD47.